FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to neurology and psychiatry, and can be used for treating central nervous system (CNS) disorders with cognitive impairment in a subject in need or at risk thereof. Wherein the CNS disorder is an amnestic mild cognitive impairment, dementia, Alzheimer's disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrphic lateral sclerosis (ALS) and cancer-therapy-related cognitive impairment. Methods for treating, delaying or slowing the progression of central nervous system (CNS) disorders with cognitive impairment, as well as reducing the rate of decline of cognitive function in said condition, comprising the step of administering to said subject a levetiracetam or a pharmaceutically acceptable salt thereof in an amount of 125-250 mg per day. Also provided are pharmaceutical compositions for oral administration once a day for implementing the methods, comprising 125-250 mg of a levetiracetam or a pharmaceutically acceptable salt thereof, wherein a levetiracetam or a pharmaceutically acceptable salt thereof is in a form suitable for sustained release.
EFFECT: group of inventions provides improvement or normalization of cognitive functions in a subject with a CNS disorder, as well as preventing or slowing the progression of said CNS disorder with cognitive impairment.
7 cl, 28 dwg, 6 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS AND COMPOSITIONS TO IMPROVE COGNITIVE FUNCTIONS | 2012 |
|
RU2792010C2 |
DERIVATIVES OF AMINOINDAZOLS AND THEIR APPLICATION AS KINASES INHIBITORS | 2003 |
|
RU2339624C2 |
SUBSTITUTED N-PHENYLPYRROLIDINYL METHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS MODULATORS OF HISTAMINE H3 RECEPTOR | 2008 |
|
RU2477721C2 |
NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINAL AGENTS AND PHARMECEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | 2003 |
|
RU2378259C2 |
17β-HSD1 AND STS INHIBITORS | 2006 |
|
RU2412196C2 |
AMINOTETRALINE DERIVATIVES CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND USING THEM IN THERAPY | 2010 |
|
RU2546649C2 |
HETEROCYCLIC ARYL SULPHONES, SUITABLE FOR TREATING DISORDERS RESPONSIVE TO 5HT RECEPTOR MODULATION | 2007 |
|
RU2451012C2 |
NOVEL COMPOUNDS AND USE THEREOF IN THERAPY | 2004 |
|
RU2412190C2 |
NEW DERIVATIVES OF HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD FOR MODULATION OF AUTOIMMUNE DISEASES, METHOD FOR PREPARING THESE COMPOUNDS | 2000 |
|
RU2255937C2 |
DERIVATIVES OF 2-OXO-1-PYRROLIDINE, METHOD FOR THEIR PREPARING AND USING | 2001 |
|
RU2291860C2 |
Authors
Dates
2018-08-24—Published
2012-02-09—Filed